“On 14 August, the WHO declared an international public health emergency in response to the growing number of human infections by the monkeypox virus, which could be transmitted by contact, fomites and bioaerosols. This declaration was followed by the publication of Mpox global strategic preparedness and response plan on August 26th”

The VACV ANCHOR poxvirus, developed by NeoVirTech and labeled “used by French Armed Forces” in 2024, is the mimetic model operated by VirexpR to characterize infectious bioaerosols using various test benches with the aim of evaluating the performance of air treatment and analysis technologies and devices under real conditions of use.

NeoVirTech, a biotechnology company developing autofluorescent virus for antiviral discovery and measurement of disinfection procedure, works on poxviruses of human and animal source since more than 10 years. VirexpR is a service company committed to improving the Indoor Air Quality of confined spaces and contributing to national and European sovereignty in terms of protection against emerging and re-emerging infectious diseases.